Ad
related to: spironolactone blocks aldosterone receptors in the heart backgoodrx.com has been visited by 100K+ users in the past month
109 S High St #100, Columbus, OH · Directions · (614) 224-4261
"GoodRx app has saved consumers $10 billion." - Fox Business
- Research You Can Rely On
Our team works hard to provide you
with the latest healthcare info.
- GoodRx®: Women’s Health
Save on Common Women’s Health Meds.
Find Resources You Can Count On.
- Do I Need Insurance?
No! Compare Our Prices to Your
Insurance & Get the Biggest Savings
- GoodRx® & Medicare
Beat your Medicare Copay!
Discover More Savings Options Today
- Research You Can Rely On
Search results
Results from the WOW.Com Content Network
Spironolactone has been identified as an inhibitor of NRG1‐ERBB4 signaling. [142] Spironolactone has been found to act as a potent inhibitor of the pannexin 1 channel, and this action appears to be involved in its antihypertensive effects independently of MR antagonism. [143] Spironolactone has been found to block hERG channels. [144]
[medical citation needed] The most common use of spironolactone is in the treatment of heart failure. [36] On its own, spironolactone is only a weak diuretic because it primarily targets the distal nephron (collecting tubule), where only small amounts of sodium are reabsorbed, but it can be combined with other diuretics to increase efficacy.
A mineralocorticoid receptor antagonist (MRA or MCRA) [1] or aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure .
Aldosterone binds to aldosterone receptors (mineralocorticoid receptors) increasing sodium reabsorption in an effort to increase blood pressure and improve fluid status in the body. When excessive sodium reabsorption occurs, there is an increasing loss of K + in the urine and can lead to clinically significant decreases, termed hypokalemia .
The mineralocorticoid receptor (or MR, MLR, MCR), also known as the aldosterone receptor or nuclear receptor subfamily 3, group C, member 2, (NR3C2) is a protein that in humans is encoded by the NR3C2 gene that is located on chromosome 4q31.1-31.2. [5] MR is a receptor with equal affinity for mineralocorticoids and glucocorticoids.
The trial was stopped early because the beneficial effect of spironolactone on all-cause death exceeded the prespecified discontinuation requirements. Spironolactone reduced the risk of death by 30% compared to placebo. Additionally, there was a 35% reduction in the risk of hospitalization for worsening heart failure in the spironolactone group.
Spirolactones are a class of functional group in organic chemistry featuring a cyclic ester attached spiro to another ring system. The name is also used to refer to a class of synthetic steroids, called steroid-17α-spirolactones, 17α-spirolactosteroids, or simply 17α-spirolactones, which feature their spirolactone group at the C17α position.
Aldosterone receptor antagonists, also known as mineralocorticoid receptor antagonist (MRA) can lower blood pressure by blocking the binding of aldosterone to the mineralocorticoid receptor. Spironolactone and eplerenone are MRAs that causes a block in the reabsorption of sodium, resulting in a decrease in blood pressure. [45] [46] eplerenone
Ad
related to: spironolactone blocks aldosterone receptors in the heart backgoodrx.com has been visited by 100K+ users in the past month
109 S High St #100, Columbus, OH · Directions · (614) 224-4261
"GoodRx app has saved consumers $10 billion." - Fox Business